Project overview
National Biofilms Innovation Centre (NBIC), UK. Proof of Concept (POC) Round 1 (Research Grant). £147,727 (£65,994.50 from NBIC, £81,732.50 from Destiny Pharma).
Antibiotic-resistant bacteria, particularly within biofilms and fungi pose a significant healthcare threat including respiratory conditions, (e.g. Cystic Fibrosis) and chronic wounds such as diabetic foot ulcers (DFU). The purpose of this NBIC study is to examine the effectiveness of a novel antimicrobial-drug series in two mechanistically-distinct and clinically relevant model systems.
Antibiotic-resistant bacteria, particularly within biofilms and fungi pose a significant healthcare threat including respiratory conditions, (e.g. Cystic Fibrosis) and chronic wounds such as diabetic foot ulcers (DFU). The purpose of this NBIC study is to examine the effectiveness of a novel antimicrobial-drug series in two mechanistically-distinct and clinically relevant model systems.
Staff
Lead researchers
Other researchers
